ALTIMMUNE, INC. Interest Expense Nonoperating
ALTIMMUNE, INC. (ALT) reported Interest Expense Nonoperating of $1.10 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement
us-gaap:InterestExpenseNonoperating · last filed 2026-08-12
- ALTIMMUNE, INC. interest expense nonoperating for the quarter ending 2026-06-30 was $1.10M, a 315.53% increase year-over-year.
- ALTIMMUNE, INC. interest expense nonoperating for the quarter ending 2026-03-31 was $1.07M, a 106700.00% increase year-over-year.
- ALTIMMUNE, INC. interest expense nonoperating for the quarter ending 2025-12-31 was $876.00K, a 87500.00% increase year-over-year.
- ALTIMMUNE, INC. interest expense nonoperating for the quarter ending 2025-09-30 was $495.00K, a 8150.00% increase year-over-year.
- ALTIMMUNE, INC. interest expense nonoperating for fiscal 2025 was $1.64M, a 18077.78% increase from fiscal 2024.
- ALTIMMUNE, INC. interest expense nonoperating for fiscal 2024 was $9.00K, a 74.29% decline from fiscal 2023.
- ALTIMMUNE, INC. interest expense nonoperating for fiscal 2023 was $35.00K.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.10M 10-Q · filed 2026-08-12 | $2.17M 10-Q · filed 2026-08-12 | $3.04M derived: sum of 3 quarters · filed 2026-08-12 | $3.54M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $1.07M 10-Q · filed 2026-05-13 | $1.94M derived: sum of 2 quarters · filed 2026-05-13 | $2.44M derived: sum of 3 quarters · filed 2026-05-13 | $2.70M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $876.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $1.37M derived: sum of 2 quarters · filed 2026-03-06 | $1.64M derived: sum of 3 quarters · filed 2026-08-12 | $1.64M 10-K · filed 2026-03-06 |
| 2025-09-30 | $495.00K 10-Q · filed 2025-11-06 | $759.00K derived: sum of 2 quarters · filed 2026-08-12 | $760.00K 10-Q · filed 2025-11-06 | $761.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $264.00K 10-Q · filed 2026-08-12 | $265.00K 10-Q · filed 2026-08-12 | $266.00K derived: sum of 3 quarters · filed 2026-08-12 | $272.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $1.00K 10-Q · filed 2026-05-13 | $2.00K derived: sum of 2 quarters · filed 2026-05-13 | $8.00K derived: sum of 3 quarters · filed 2026-05-13 | $9.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $7.00K derived: sum of 2 quarters · filed 2026-03-06 | $8.00K derived: sum of 3 quarters · filed 2026-03-06 | $9.00K 10-K · filed 2026-03-06 |
| 2024-09-30 | $6.00K 10-Q · filed 2025-11-06 | $7.00K derived: sum of 2 quarters · filed 2025-11-06 | $8.00K 10-Q · filed 2025-11-06 | $10.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $1.00K 10-Q · filed 2025-08-12 | $2.00K 10-Q · filed 2025-08-12 | $4.00K derived: sum of 3 quarters · filed 2025-08-12 | $33.00K derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $1.00K 10-Q · filed 2025-05-13 | $3.00K derived: sum of 2 quarters · filed 2025-05-13 | $32.00K derived: sum of 3 quarters · filed 2025-05-13 | $34.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $31.00K derived: sum of 2 quarters · filed 2025-02-27 | $33.00K derived: sum of 3 quarters · filed 2025-02-27 | $35.00K 10-K · filed 2025-02-27 |
| 2023-09-30 | $29.00K 10-Q · filed 2024-11-12 | $31.00K derived: sum of 2 quarters · filed 2024-11-12 | $33.00K 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $2.00K 10-Q · filed 2024-08-08 | $4.00K 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |